Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population
Abstract Introduction Real-world use of immunomodulating therapy (IMT) in patients with systemic sclerosis (SSc) was investigated for the first time in a descriptive, retrospective cohort analysis of claims made in a healthcare insurance database to characterize treatment patterns and their alignmen...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2019-11-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1007/s40744-019-00181-8 |
| _version_ | 1818218274687549440 |
|---|---|
| author | Sara L. Gale Huong Trinh Nitya Mathew Angelika Jahreis Celia J. F. Lin Khaled Sarsour |
| author_facet | Sara L. Gale Huong Trinh Nitya Mathew Angelika Jahreis Celia J. F. Lin Khaled Sarsour |
| author_sort | Sara L. Gale |
| collection | DOAJ |
| description | Abstract Introduction Real-world use of immunomodulating therapy (IMT) in patients with systemic sclerosis (SSc) was investigated for the first time in a descriptive, retrospective cohort analysis of claims made in a healthcare insurance database to characterize treatment patterns and their alignment with SSc disease manifestations. Methods Treatment patterns and disease manifestations, symptoms, complications, and comorbidities were assessed in patients with SSc enrolled in a US healthcare claims database who received treatment between January 2006 and December 2013 and for whom data were available 6 months before and 12 months after SSc diagnosis. Results Among 7812 eligible patients, 6852 received treatments of interest for SSc and 2404 (30.8%) received IMT during the first year after SSc diagnosis. In the first year after diagnosis, the most common claims were for antibiotics (61.7%), opioids (50.6%), glucocorticoids (46.5%), and proton pump inhibitors (35.4%); the most common organs involved with complications among patients with SSc were lung (30.5%), heart (17.4%), and gastrointestinal tract (22.4%); the most common signs or symptoms were musculoskeletal (16.1%) and fatigue (10.5%); 1035 patients (15.1%) had infections and 14 (0.2%) had malignancies. Among patients who received IMT, 43.8% received at least hydroxychloroquine and 21.1% received at least methotrexate; 460 patients switched to a second IMT, 23.0% to at least methotrexate and 22.8% to at least mycophenolate mofetil. The most common comorbidities reported with first IMT were in lung (11.8%), overlap syndrome (8.4%), heart (5.3%), and gastrointestinal (6.8%) categories. Conclusion One-third of patients with SSc in the healthcare claims population received IMTs during the first year after diagnosis. However, patients who received IMTs had disease manifestations similar to those of the overall SSc healthcare claims population. |
| first_indexed | 2024-12-12T07:21:10Z |
| format | Article |
| id | doaj.art-5a5a658ce0f247b899cb0740c5cc735d |
| institution | Directory Open Access Journal |
| issn | 2198-6576 2198-6584 |
| language | English |
| last_indexed | 2024-12-12T07:21:10Z |
| publishDate | 2019-11-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj.art-5a5a658ce0f247b899cb0740c5cc735d2022-12-22T00:33:20ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842019-11-0171899910.1007/s40744-019-00181-8Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims PopulationSara L. GaleHuong TrinhNitya MathewAngelika JahreisCelia J. F. LinKhaled SarsourAbstract Introduction Real-world use of immunomodulating therapy (IMT) in patients with systemic sclerosis (SSc) was investigated for the first time in a descriptive, retrospective cohort analysis of claims made in a healthcare insurance database to characterize treatment patterns and their alignment with SSc disease manifestations. Methods Treatment patterns and disease manifestations, symptoms, complications, and comorbidities were assessed in patients with SSc enrolled in a US healthcare claims database who received treatment between January 2006 and December 2013 and for whom data were available 6 months before and 12 months after SSc diagnosis. Results Among 7812 eligible patients, 6852 received treatments of interest for SSc and 2404 (30.8%) received IMT during the first year after SSc diagnosis. In the first year after diagnosis, the most common claims were for antibiotics (61.7%), opioids (50.6%), glucocorticoids (46.5%), and proton pump inhibitors (35.4%); the most common organs involved with complications among patients with SSc were lung (30.5%), heart (17.4%), and gastrointestinal tract (22.4%); the most common signs or symptoms were musculoskeletal (16.1%) and fatigue (10.5%); 1035 patients (15.1%) had infections and 14 (0.2%) had malignancies. Among patients who received IMT, 43.8% received at least hydroxychloroquine and 21.1% received at least methotrexate; 460 patients switched to a second IMT, 23.0% to at least methotrexate and 22.8% to at least mycophenolate mofetil. The most common comorbidities reported with first IMT were in lung (11.8%), overlap syndrome (8.4%), heart (5.3%), and gastrointestinal (6.8%) categories. Conclusion One-third of patients with SSc in the healthcare claims population received IMTs during the first year after diagnosis. However, patients who received IMTs had disease manifestations similar to those of the overall SSc healthcare claims population.http://link.springer.com/article/10.1007/s40744-019-00181-8DatabasesImmunosuppressive agentsPatterns of careSystemic sclerosisScleroderma |
| spellingShingle | Sara L. Gale Huong Trinh Nitya Mathew Angelika Jahreis Celia J. F. Lin Khaled Sarsour Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population Rheumatology and Therapy Databases Immunosuppressive agents Patterns of care Systemic sclerosis Scleroderma |
| title | Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population |
| title_full | Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population |
| title_fullStr | Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population |
| title_full_unstemmed | Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population |
| title_short | Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population |
| title_sort | characterizing disease manifestations and treatment patterns among adults with systemic sclerosis a retrospective analysis of a us healthcare claims population |
| topic | Databases Immunosuppressive agents Patterns of care Systemic sclerosis Scleroderma |
| url | http://link.springer.com/article/10.1007/s40744-019-00181-8 |
| work_keys_str_mv | AT saralgale characterizingdiseasemanifestationsandtreatmentpatternsamongadultswithsystemicsclerosisaretrospectiveanalysisofaushealthcareclaimspopulation AT huongtrinh characterizingdiseasemanifestationsandtreatmentpatternsamongadultswithsystemicsclerosisaretrospectiveanalysisofaushealthcareclaimspopulation AT nityamathew characterizingdiseasemanifestationsandtreatmentpatternsamongadultswithsystemicsclerosisaretrospectiveanalysisofaushealthcareclaimspopulation AT angelikajahreis characterizingdiseasemanifestationsandtreatmentpatternsamongadultswithsystemicsclerosisaretrospectiveanalysisofaushealthcareclaimspopulation AT celiajflin characterizingdiseasemanifestationsandtreatmentpatternsamongadultswithsystemicsclerosisaretrospectiveanalysisofaushealthcareclaimspopulation AT khaledsarsour characterizingdiseasemanifestationsandtreatmentpatternsamongadultswithsystemicsclerosisaretrospectiveanalysisofaushealthcareclaimspopulation |